Cargando…

Ethics and IVF add-ons: We need to talk about it

In vitro fertilization (IVF) ‘add-ons’ are adjunct treatments used in addition to standard IVF protocols, in an attempt to improve success rates. However, the benefits for add-ons are often not supported by high-quality evidence. Nevertheless, many infertile patients are willing to try anything that...

Descripción completa

Detalles Bibliográficos
Autores principales: Braga, Daniela Paes de Almeida Ferreira, Setti, Amanda Souza, Borges Jr., Edson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Brazilian Society of Assisted Reproduction 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355445/
https://www.ncbi.nlm.nih.gov/pubmed/35930629
http://dx.doi.org/10.5935/1518-0557.20220030
_version_ 1784763296247709696
author Braga, Daniela Paes de Almeida Ferreira
Setti, Amanda Souza
Borges Jr., Edson
author_facet Braga, Daniela Paes de Almeida Ferreira
Setti, Amanda Souza
Borges Jr., Edson
author_sort Braga, Daniela Paes de Almeida Ferreira
collection PubMed
description In vitro fertilization (IVF) ‘add-ons’ are adjunct treatments used in addition to standard IVF protocols, in an attempt to improve success rates. However, the benefits for add-ons are often not supported by high-quality evidence. Nevertheless, many infertile patients are willing to try anything that might help them to improve their chances of having a baby. Therefore, the use of add-ons has been widespread and has led to extensive debate and discussion. The goal of this manuscript was to discuss the ethics underling the use of adjunct therapies in clinical practice before their safety has been thoroughly ascertained. IVF patients are routinely offered and charged for a wide range of adjunct treatments that they are told may improve their chance of a live birth, despite there being no clinical evidence supporting such efficacy. Add-on treatments are well accepted by most infertile patients, especially those who have already started their IVF treatments. A particular concern is that many clinics around the world are advertising and offering clinical adjuncts to infertile couples undergoing IVF, however, information on add-ons is often inaccurate. Data concerning the lack of scientific evidence supporting add-on efficacy and whether an add-on may cause unanticipated harm or worsen treatment outcomes is not available on most websites. IVF patients are a vulnerable population, thus there is a need for transparency about interventions for IVF, including uncertainties and risks, to support patient decision-making regarding the use of certain adjunctive therapies. Such information can be provided by clear guidelines and effective regulation.
format Online
Article
Text
id pubmed-9355445
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Brazilian Society of Assisted Reproduction
record_format MEDLINE/PubMed
spelling pubmed-93554452022-08-09 Ethics and IVF add-ons: We need to talk about it Braga, Daniela Paes de Almeida Ferreira Setti, Amanda Souza Borges Jr., Edson JBRA Assist Reprod Editorial In vitro fertilization (IVF) ‘add-ons’ are adjunct treatments used in addition to standard IVF protocols, in an attempt to improve success rates. However, the benefits for add-ons are often not supported by high-quality evidence. Nevertheless, many infertile patients are willing to try anything that might help them to improve their chances of having a baby. Therefore, the use of add-ons has been widespread and has led to extensive debate and discussion. The goal of this manuscript was to discuss the ethics underling the use of adjunct therapies in clinical practice before their safety has been thoroughly ascertained. IVF patients are routinely offered and charged for a wide range of adjunct treatments that they are told may improve their chance of a live birth, despite there being no clinical evidence supporting such efficacy. Add-on treatments are well accepted by most infertile patients, especially those who have already started their IVF treatments. A particular concern is that many clinics around the world are advertising and offering clinical adjuncts to infertile couples undergoing IVF, however, information on add-ons is often inaccurate. Data concerning the lack of scientific evidence supporting add-on efficacy and whether an add-on may cause unanticipated harm or worsen treatment outcomes is not available on most websites. IVF patients are a vulnerable population, thus there is a need for transparency about interventions for IVF, including uncertainties and risks, to support patient decision-making regarding the use of certain adjunctive therapies. Such information can be provided by clear guidelines and effective regulation. Brazilian Society of Assisted Reproduction 2022 /pmc/articles/PMC9355445/ /pubmed/35930629 http://dx.doi.org/10.5935/1518-0557.20220030 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
Braga, Daniela Paes de Almeida Ferreira
Setti, Amanda Souza
Borges Jr., Edson
Ethics and IVF add-ons: We need to talk about it
title Ethics and IVF add-ons: We need to talk about it
title_full Ethics and IVF add-ons: We need to talk about it
title_fullStr Ethics and IVF add-ons: We need to talk about it
title_full_unstemmed Ethics and IVF add-ons: We need to talk about it
title_short Ethics and IVF add-ons: We need to talk about it
title_sort ethics and ivf add-ons: we need to talk about it
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355445/
https://www.ncbi.nlm.nih.gov/pubmed/35930629
http://dx.doi.org/10.5935/1518-0557.20220030
work_keys_str_mv AT bragadanielapaesdealmeidaferreira ethicsandivfaddonsweneedtotalkaboutit
AT settiamandasouza ethicsandivfaddonsweneedtotalkaboutit
AT borgesjredson ethicsandivfaddonsweneedtotalkaboutit